Table 2. Changes in β-cell function and insulin sensitivity after 6 months of sitagliptin treatment.
| Baseline (n=24) | After treatment (n=24) | P value | |
|---|---|---|---|
| Glucose, mmol/L | |||
| 0 min | 9.10±0.64 | 8.62±0.58 | 0.209 |
| 120 min | 16.52±0.89 | 15.08±1.03 | 0.072 |
| Insulin, pmol/L | |||
| 0 min | 45.21±5.36 | 52.36±7.64 | 0.361 |
| 120 min | 148.62±21.27 | 234.06±29.88 | 0.001 |
| C-peptide, nmol/L | |||
| 0 min | 0.68±0.09 | 0.63±0.36 | 0.695 |
| 120 min | 1.94±0.17 | 1.91±0.98 | 0.760 |
| Glucagon, ng/L | |||
| 0 min | 72.73±3.54 | 79.54±17.32 | 0.140 |
| 120 min | 74.07±3.26 | 82.47±21.06 | 0.120 |
| Total AUC (insulin/glucose) | 8.76±1.53 | 15.01±2.04 | 0.001 |
| HOMA-IR | 2.78±0.39 | 3.09±0.70 | 0.797 |
| Matsuda index | 6.37±0.96 | 5.22±0.73 | 0.317 |
| Insulinogenic index | 0.63±0.11 | 1.18±0.27 | 0.001 |
| HOMA-β | 26.95±3.31 | 33.57±4.15 | 0.061 |
| Total AUC (glucagon/insulin) | 1.95±1.09 | 1.56±1.03 | 0.303 |
| HbA1c, % | 7.22±0.26 | 6.96±0.20 | 0.098 |
Values are presented as mean±standard error.
AUC, area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; HbA1c, glycosylated hemoglobin.